Stifel Financial Corp Arrowhead Pharmaceuticals, Inc. Transaction History

Stifel Financial Corp

$93.2 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$28.0 - $40.56 $40,656 - $58,893	-1,452 Reduced 6.83%	19,821 $803,000
Q3 2022 Nov 14, 2022	SELL	$29.63 - $48.31 $9,066 - $14,782	-306 Reduced 1.42%	21,273 $703,000
Q2 2022 Aug 15, 2022	SELL	$27.79 - $50.61 $9,393 - $17,106	-338 Reduced 1.54%	21,579 $760,000
Q1 2022 May 13, 2022	SELL	$39.62 - $69.97 $31,339 - $55,346	-791 Reduced 3.48%	21,917 $1.01 Million
Q4 2021 Feb 14, 2022	SELL	$58.09 - $82.51 $8,423 - $11,963	-145 Reduced 0.63%	22,708 $1.51 Million
Q3 2021 Nov 15, 2021	SELL	$58.38 - $84.96 $4,845 - $7,051	-83 Reduced 0.36%	22,853 $1.43 Million
Q2 2021 Aug 13, 2021	BUY	$62.15 - $90.32 $23,368 - $33,960	376 Added 1.67%	22,936 $1.9 Million
Q1 2021 May 14, 2021	BUY	$61.35 - $90.47 $10,858 - $16,013	177 Added 0.79%	22,560 $1.5 Million
Q4 2020 Feb 12, 2021	SELL	$43.82 - $85.37 $3,637 - $7,085	-83 Reduced 0.37%	22,383 $1.72 Million
Q3 2020 Nov 16, 2020	BUY	$33.21 - $51.27 $25,405 - $39,221	765 Added 3.53%	22,466 $967,000
Q2 2020 Aug 14, 2020	SELL	$26.12 - $43.27 $44,717 - $74,078	-1,712 Reduced 7.31%	21,701 $937,000
Q1 2020 May 14, 2020	SELL	$20.56 - $63.12 $11,554 - $35,473	-562 Reduced 2.34%	23,413 $675,000
Q4 2019 Feb 13, 2020	SELL	$28.14 - $73.01 $2,617 - $6,789	-93 Reduced 0.39%	23,975 $1.52 Million
Q3 2019 Nov 13, 2019	SELL	$26.26 - $34.86 $577 - $766	-22 Reduced 0.09%	24,068 $678,000
Q2 2019 Aug 14, 2019	SELL	$17.43 - $28.82 $6,588 - $10,893	-378 Reduced 1.54%	24,090 $641,000
Q1 2019 May 14, 2019	SELL	$12.05 - $20.18 $2,747 - $4,601	-228 Reduced 0.92%	24,468 $450,000
Q4 2018 Feb 13, 2019	BUY	$10.74 - $19.7 $265,235 - $486,511	24,696 New	24,696 $306,000

Others Institutions Holding ARWR

# of Institutions

294

Shares Held

90.8M

Call Options Held

155K

Put Options Held

426K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.01B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.

Account